Fig. 1

Short Form-36 (SF-36) domain scores at month 3. Spydergrams of SF-36 domain scores at month 3, with a US age- and gender-matched normative population as a comparator. a Placebo at baseline and month 3. b Tofacitinib 5 mg twice daily (BID) at baseline and month 3. c Tofacitinib 10 mg BID at baseline and month 3. d Baseline scores for each treatment group. e Weighted combined baseline score + placebo + tofacitinib 5 mg BID + tofacitinib 10 mg BID. a-d Treatment group baselines (using separate colors in d). e Weighted combined baseline across all treatment groups. Placebo, n = 122 at baseline, and n = 108 at month 3; tofacitinib 5 mg BID, n = 239 at baseline and n = 235 at month 3; tofacitinib 10 mg, n = 243 at baseline and n = 224 at month 3. Study values were normalized using means and SDs. See Ware et al. [38]. BP bodily pain, GH general health, MH mental health, PF physical function, RE role emotional, RP role physical, SF social functioning, VT vitality